Valentino J Stella

USPTO Granted Patents = 50 (Patent Applications = 7)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 4.1

ph-index = 21

Forward Citations = 2,954(Granted Patents)

Forward Citations (Not Self Cited) = 2,890(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Rigel Pharmaceuticals, Incorporated

patents

7 out of 66

Helsinn Healthcare Sa

patents

4. 4 out of 924

Gilead Sciences, Inc.

Interx Research Corporation

patents

9. 2 out of 2

Praxis Bioresearch, LLC

patents

10. 1 out of 12,164

Bayer Aktiengesellschaft

patents

11. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

12. 1 out of 832,880

Other

patents

Years Active: 1979-2024

Loading Chart...

Areas of Expertise:

Prodrugs

Cyclic Prodrugs

Antiviral Nucleotide Analogs

Neurokinin Receptor Modulators

Aqueous Solubility

Micronization Methods

Pharmaceutical Formulations

Hindered Alcohols

Piperaziniums

CGRP Receptor Antagonists

Chloromethyl Dialkylphosphates

Taxol Derivatives

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12071421 - Process for the synthesis of substituted chloromethyl dialkylphosphates (2024-08-27),

2. 11919836 - Prodrugs of fencamfamine (2024-03-05),

3. 11312698 - Fosnetupitant chloride hydrochloride having improved stability (2022-04-26),

4. 11254695 - Soluble C5aR antagonists (2022-02-22),

5. 11091507 - Methods of treating Parkinson's disease (2021-08-17),

6. 10717721 - Substituted piperaziniums for the treatment of emesis (2020-07-21),

7. 10662146 - Prodrugs of fencamfamine (2020-05-26),

8. 10577381 - Prodrugs of 2,4-pyrimidinediamine compounds and their uses (2020-03-03),

9. 10487098 - Soluble C5aR antagonists (2019-11-26),

10. 10329314 - Soluble C5aR antagonists (2019-06-25),

11. 10208073 - Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator (2019-02-19),

12. 10174061 - Carbidopa and L-dopa prodrugs and methods of use (2019-01-08),

13. 9908907 - Substituted piperaziniums for the treatment of emesis (2018-03-06),

14. 9532998 - Prodrugs of 2,4-pyrimidinediamine compounds and their uses (2017-01-03),

15. 9446059 - Carbidopa and L-dopa prodrugs and methods of use (2016-09-20),

Sure, here is the article about inventor Valentino J Stella:

Title: Innovator Spotlight: Valentino J Stella

Introduction:

Valentino J Stella is a prominent inventor based in Lawrence, Kansas (US). With an impressive track record of 49 patents to his name, Stella has made significant contributions to the field of pharmaceuticals. His innovative work has led to the development of groundbreaking pharmaceutical compositions and novel prodrug derivatives.

Latest Patents:

Two of Stella's latest patents include:

- "Prodrugs of fencamfamine": Stella's patent discloses pharmaceutical compositions containing fencamfamine or its related prodrug derivatives for targeted therapeutic applications, along with methods for synthesizing these compositions.

- "Fosnetupitant chloride hydrochloride having improved stability": This patent highlights Stella's development of fosnetupitant chloride hydrochloride with enhanced stability, featuring a distinct chemical structure.

Career Highlights:

Stella has worked with esteemed organizations such as the University of Kansas and Rigel Pharmaceuticals, Incorporated. His expertise in the pharmaceutical industry has been instrumental in advancing the field and improving patient care through innovative drug solutions.

Collaborations:

Throughout his career, Stella has collaborated with accomplished professionals, including Somasekhar Bhamidipati and Rajinder Paul Singh. These collaborations have fostered a culture of innovation and knowledge sharing, leading to the successful development of novel pharmaceutical products.

Conclusion:

Valentino J Stella's dedication to innovation and his relentless pursuit of excellence have solidified his reputation as a top inventor in the pharmaceutical sector. His inventive spirit and collaborative efforts continue to drive progress in the industry, ultimately benefiting patients worldwide.

I hope this article provides valuable insights into the remarkable work of Valentino J Stella in the realm of pharmaceutical innovations.

This text is generated by artificial intelligence and may not be accurate.